DaVita Inc. 4th Quarter 2024 Results
DaVita Inc. (NYSE: DVA) announced its financial and operational results for the fourth quarter ended December 31, 2024. The company reported strong performance despite facing various challenges throughout the year.
CEO Javier Rodriquez emphasized, "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range. Our focus for 2025 is to enhance clinical outcomes and quality of life for our patients and teammates. We are committed to being a force for positive change within the healthcare system."
Quarterly Highlights
In the fourth quarter, consolidated revenues reached $3.295 billion, contributing to total annual revenues of $12.816 billion. The operating income recorded for the quarter was $565 million, while the adjusted operating income was $491 million. Over the entire year, DaVita achieved an operating income of $2.090 million and an adjusted operating income of $1.981 million.
Earnings and Cash Flow Performance
The diluted earnings per share stood at $3.09 for the quarter, with adjusted diluted earnings per share at $2.24. For the year, the diluted earnings per share increased to $10.73, with an adjusted figure of $9.68. Operating cash flow for Q4 was $548 million, while free cash flow amounted to $281 million. The total for the year reached $2.022 billion in operating cash flow and $1.162 billion in free cash flow.
Share Repurchase Program
During the last quarter of 2024, DaVita repurchased 2.3 million shares at an average price of $156.46 per share. Through February 2025, the company has continued its buyback by acquiring an additional 0.8 million shares at an average price of $158.48 per share.
Dialysis Metrics and Operational Insights
Total U.S. dialysis treatments in Q4 reached 7,278,605, averaging 91,786 treatments per day. This represented a slight decrease of 1.4% from the previous quarter, with normalized non-acquired treatment growth showing a minor decrease of 0.3% year-over-year.
Financial Drivers
The fluctuations in revenue are attributed to seasonal impacts, including flu season effects and typical business variations. Increased average reimbursement rates, revenue cycles, and hikes in hospital dialysis rates significantly contributed to year-to-date figures.
Patient care costs saw an upward trend due to center closure expenses, insurance costs, and other direct operational expenses associated with dialysis centers. These were somewhat offset by reductions in medical supply costs.
Strategic Review and Closure Costs
The company has undergone a strategic review of outpatient clinic capacities, initiated due to low patient census rates from the pandemic. This review has led to higher than typical expenses for center capacity closures, impacting the fiscal results significantly. Charges incurred for U.S. dialysis center closures amounted to approximately $24.2 million in Q4 alone, contributing to a combined impact on patient care costs and administrative expenses.
2025 Guidance and Outlook
Looking ahead, DaVita Inc. provided a cautious guidance outlook for 2025. Due to significant and unpredictable risks, the company is focused on maintaining agility and resilience in its financial operations. The effective income tax rate for adjusted income is anticipated to vary as the company responds to changing market dynamics and regulatory environments.
Frequently Asked Questions
What were the major highlights from DaVita's Q4 2024 report?
DaVita reported revenues of $3.295 billion and an operating income of $565 million, achieving strong performance with a solid earnings per share figure.
How has the CEO characterized the performance of DaVita for 2024?
CEO Javier Rodriquez noted that despite facing unique challenges, the company finished strong, marking a commitment to enhancing patient care and operational efficiency.
What were the operating cash flow results for DaVita in the last quarter?
The operating cash flow in Q4 of 2024 was reported at $548 million, bolstered by significant annual cash flow results totaling $2.022 billion.
What factors contributed to changes in DaVita's revenue this quarter?
Revenue changes were driven primarily by seasonal impacts, fluctuations in treatment volumes, and adjustments in reimbursement rates.
What steps is DaVita taking for future growth?
DaVita plans to focus on improving clinical outcomes and quality of life for patients and is continuously evaluating operational efficiencies in response to market demands.
